Study of radiation plus chemo and immunotherapy for rectal cancer
Part of Cancer clinical trials.
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that is adenocarcinoma (the most common type).
- You are between 18 and 74 years old.
- You are in good general health (ECOG score 0 or 1).
- Your tumor is stage cT3-4N0M0 or TanyN1-2M0 and the bottom edge is within 10 cm of the anus.
- You have not had prior pelvic radiation or other cancer treatments in the last 4 weeks.
- Your heart, liver, kidney, and blood cell counts are adequate as checked by standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial is testing a combination of chemotherapy and targeted therapy with or without adding radiation and two immunotherapy drugs for advanced rectal cancer that has spread. It looks at whether adding radiation and immunotherapy can help control the cancer better for people with certain genetic types (RAS mutation and pMMR).
This trial tests whether adding a very low dose of radiation to a combination of immunotherapy (pucotenlimab) and chemotherapy (CAPEOX) can help shrink rectal cancer tumors that have not spread. It is for people with locally advanced rectal cancer that is pMMR (meaning the cancer cells have normal DNA repair).
This trial tests a combination of two immunotherapy drugs, chemotherapy, and bevacizumab given before surgery for locally advanced rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and radiation before surgery for people with a specific type of high-risk rectal cancer. The goal is to see if adding these drugs can improve treatment results.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.